News

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a ...
Nature27d
When lymphocytes run out of steam - Nature
Lymphocytes are immune cells that play a crucial part in protection against microorganisms such ... The development of more-specific inhibitors of CTPS1 will aid the further investigation of this ...
Infectious Disease Advisor2h
FDA Puts Clinical Hold on Gilead’s Trials for 2 HIV Drug Candidates
Gilead’s HIV treatment trials involving GS-1720 and GS-4182 have been put on clinical hold by the Food and Drug Administration.
Leaving Cert biology: Plenty of choice but challenging in places
The Leaving Cert biology paper (higher level) has been well-received by teacher and students alike, with praise for the ...
Hub1d
Federal budget cuts slow pace of breakthrough autoimmune therapies
Federal budget cuts have created "a climate of anxiety" among medical researchers, says Maximilian F. Konig, a rheumatologist ...
Why the appendix is much more important than we once thought
The appendix may play a further role in protecting the gastrointestinal system from invading pathogens. This would explain ...
iPSC-CAR-NK Cell Therapy Clinical Result Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...
Creative Biolabs Delivers End-To-End Solutions For TIL Therapy Development, Propelling Cancer Immunotherapy
At the cutting edge of TIL therapy development, Creative Biolabs offers end-to-end and integrated solutions dedicated to the unique needs of this dis ...